http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1289508-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24ce2ecfefe8e997ca7a1fb6f98bafc9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 |
| filingDate | 2001-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fc4533c550abd37d6ce3de8a95d969a |
| publicationDate | 2003-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1289508-A2 |
| titleOfInvention | Method for the prevention of apoptosis |
| abstract | and effect has been attributed to inhibition of complement, but heparin also exhibits other activities that can decrease ischemia-reperfusion. To further analyze these mechanisms, we compared heparin and a non-anticoagulant O-desulfated heparin with greatly reduced anti-complement activity. Administered during reperfusion of the coronary artery in a canine myocardial infarction model, both heparin and O-desulfated heparin equally reduce the adhesion of neutrophils to the artery endothelium ischemic and reperfused coronary, influx of neutrophils into the ischemic and reperfused myocardium, myocardial necrosis and release of creatine kinase into the plasma. Heparin and O-desulfated heparin also prevent dysfunction of endothelial-dependent coronary relaxation following ischemic injury. In addition, heparin and O-desulfated heparin inhibit the translocation of human endothelial factllules and reduce the NF-λB DNA binding in human endothelium and ischemic and reperfused rat myocardium. Thus, heparin and non-anticoagulant heparin decrease the ischemia-reperfusion injury by interrupting multiple levels of the inflammatory cascade and, according to a new observation, heparins inhibit activation of the proinflammatory transcription factor NF-λB. |
| priorityDate | 2000-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 327.